

10/509715

DT09 Rec'd PCT/PTO 01 OCT 2004

Atty. Docket No.: LeA 35 949

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3/A

APPLICANTS: Golz, *et al.*

SERIAL NO.: National Stage Filing for PCT/EP2003/002959

FILING DATE: herewith

TITLE: Diagnostics and Therapeutics for Diseases Associated with N-Formyl Peptide Receptor Like 1 (FPRL1)

PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Preliminary Amendment is submitted in the above-captioned application. Please amend the application as follows:

In the Claims

Please amend claims 1-12 and 18-26 as shown in the attached sheets (pages 3-7 of this amendment).

Remarks


By way of this Preliminary Amendment, claims 1-26 are pending. Claims 1-12 and 18-26 have been amended. These claim cancellations and amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments and additions.

Conclusion

Applicants believe that the subject matter of the pending claims is patentable and that the instant application should accordingly be allowed. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-6450.

Respectfully submitted,

Dated: September 29, 2004


Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
(Tel) (203) 812-6450
(Fax) (203) 812-6459